Molecular prognostic markers in malignant mesothelioma

Lung Cancer

Volumn 49, Issue SUPPL. 1, 2005, Pages

  Kumar, Priya ^a   Kratzke, Robert A ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Malignant mesothelioma; Prognostic markers; Tumor

Indexed keywords

5,6 DIHYDROAZACITIDINE; ANGIOGENESIS INHIBITOR; ANGIOSTATIC PROTEIN; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; ASBESTOS; BATIMASTAT; CATALASE; CELECOXIB; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYTOSINE DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; GELATINASE A; GELATINASE B; KI 67 ANTIGEN; MANGANESE SUPEROXIDE DISMUTASE; PROTEIN BAK; PROTEIN P14ARF; PROTEIN P16INK4A; PROTEIN P21; PROTEIN P27; PROTEIN P53; RETINOBLASTOMA PROTEIN; SODIUM PHENYLBUTARATE; SU 1498; SYNDECAN 1; THROMBOSPONDIN 1; TUMOR MARKER; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR; VIRUS VACCINE;

ADVANCED CANCER; ANGIOGENESIS; ARTICLE; ASPIRATION PNEUMONIA; CANCER CHEMOTHERAPY; CANCER RESEARCH; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CHROMOSOME 9P; CLINICAL TRIAL; DISEASE COURSE; DRUG SAFETY; EPITHELIUM TUMOR; GENE LOCUS; GENE SEQUENCE; HUMAN; LETHALITY; LYMPH NODE METASTASIS; MALIGNANT MESOTHELIOMA; MEDICAL DECISION MAKING; MEDICAL INFORMATION; MITOSIS; MYELODYSPLASIA; NONHUMAN; PATIENT CARE; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SIMIAN VIRUS 40; STANDARD; SURVIVAL TIME;

CELL CYCLE PROTEINS; HUMANS; MESOTHELIOMA; PLEURAL NEOPLASMS; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL;

EID: 20444403009     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2005.03.012     Document Type: Article

References (61)

1. D. Curran, T. Sahmoud, P. Therasse, J. van Meerbeeck, P.E. Postmus, and G. Giaccone Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience J Clin Oncol 16 1998 145 152
2. J.E. Herndon, M.R. Green, A.P. Chahinian, J.M. Corson, Y. Suzuki, and N.J. Vogelzang Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B Chest 113 1998 723 731
3. H. Dazzi, P.S. Hasleton, N. Thatcher, S. Wilkes, R. Swindell, and A.K. Chatterjee Malignant pleural mesothelioma and epidermal growth factor receptor (EGF-R). Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody Br J Cancer 61 1990 924 926
4. K.J. O'Byrne, J.G. Edwards, and D.A. Waller Clinico-pathological and biological prognostic factors in pleural malignant mesothelioma Lung Cancer 45 Suppl. 1 2004 S45 S48
5. R. Govindan, R.A. Kratzke, J.E. Herndon II, G.A. Niehans, R. Vollmer, and D. Watson Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B Clin Cancer Res 11 2005 2300 2304
6. P.A. Janne, M.L. Taffaro, R. Salgia, and B.E. Johnson Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma Cancer Res 62 2002 5242 5247
7. K.J. O'Byrne, A.G. Dalgleish, M.J. Browning, W.P. Steward, and A.L. Harris The relationship between angiogenesis and the immune response in carcinogenesis and the progression of malignant disease Eur J Cancer 36 2000 151 169
8. M. Tsujii, S. Kawano, and R.N. DuBois Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential Proc Natl Acad Sci USA 94 1997 3336 3340
9. K. Uefuji, T. Ichikura, and H. Mochizuki Cyclooxygenase-2 expression is related to prostaglandin biosynthesis and angiogenesis in human gastric cancer Clin Cancer Res 6 2000 135 138
10. J.G. Edwards, S.P. Faux, S.M. Plummer, K.R. Abrams, R.A. Walker, and D.A. Waller Cyclooxygenase-2 expression is a novel prognostic factor in malignant mesothelioma Clin Cancer Res 8 2002 1857 1862
11. A.W. Langerak, P.A. De Laat, C.A. Van Der Linden-Van Beurden, M. Delahaye, T.H. Van Der Kwast, and H.C. Hoogsteden Expression of platelet-derived growth factor (PDGF) and PDGF receptors in human malignant mesothelioma in vitro and in vivo J Pathol 178 1996 151 160
12. T. Shimada, H. Hiraishi, and A. Terano Hepatocyte growth factor protects gastric epithelial cells against ceramide-induced apoptosis through induction of cyclooxygenase-2 Life Sci 68 2000 539 546
13. W. Xie, and H.R. Herschman Transcriptional regulation of prostaglandin synthase 2 gene expression by platelet-derived growth factor and serum J Biol Chem 271 1996 31742 31748
14. A. Catalano, L. Graciotti, L. Rinaldi, G. Raffaelli, S. Rodilossi, and P. Betta Preclinical evaluation of the nonsteroidal anti-inflammatory agent celecoxib on malignant mesothelioma chemoprevention Int J Cancer 109 2004 322 328
15. S. Kumar-Singh, J. Weyler, M.J. Martin, P.B. Vermeulen, and E. Van Marck Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and -2, and TGF beta expression J Pathol 189 1999 72 78
16. Y. Ohta, V. Shridhar, R.K. Bright, G.P. Kalemkerian, W. Du, and M. Carbone VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours Br J Cancer 81 1999 54 61
17. C.J. Sherr Cancer cell cycles Science 274 1996 1672 1677
18. R.A. Kratzke, G.A. Otterson, C.E. Lincoln, S. Ewing, H. Oie, and J. Geradts Immunohistochemical analysis of the p16INK4 cyclin-dependent kinase inhibitor in malignant mesothelioma J Natl Cancer Inst 87 1995 1870 1875
19. G.A. Otterson, R.A. Kratzke, A. Coxon, Y.W. Kim, and F.J. Kaye Absence of p16INK4 protein is restricted to the subset of lung cancer lines that retains wildtype RB Oncogene 9 1994 3375 3378
20. M. Carbone, R.A. Kratzke, and J.R. Testa The pathogenesis of mesothelioma Semin Oncol 29 2002 2 17
21. R.A. Kratzke, T.M. Greatens, J.B. Rubins, M.A. Maddaus, D.E. Niewoehner, and G.A. Niehans Rb and p16INK4a expression in resected non-small cell lung tumors Cancer Res 56 1996 3415 3420
22. G.A. Niehans, R.A. Kratzke, M.K. Froberg, D.M. Aeppli, P.L. Nguyen, and J. Geradts G1 checkpoint protein and p53 abnormalities occur in most invasive transitional cell carcinomas of the urinary bladder Br J Cancer 80 1999 1175 1184
23. J.Q. Cheng, S.C. Jhanwar, Y.Y. Lu, and J.R. Testa Homozygous deletions within 9p21-p22 identify a small critical region of chromosomal loss in human malignant mesotheliomas Cancer Res 53 1993 4761 4763
24. T. Taguchi, S.C. Jhanwar, J.M. Siegfried, S.M. Keller, and J.R. Testa Recurrent deletions of specific chromosomal sites in 1p, 3p, 6q, and 9p in human malignant mesothelioma Cancer Res 53 1993 4349 4355
25. J.Q. Cheng, S.C. Jhanwar, W.M. Klein, D.W. Bell, W.C. Lee, and D.A. Altomare p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma Cancer Res 54 1994 5547 5551
26. S. Xio, D. Li, J. Vijg, D.J. Sugarbaker, J.M. Corson, and J.A. Fletcher Codeletion of p15 and p16 in primary malignant mesothelioma Oncogene 11 1995 511 515
27. B.L. Samuels, J.N. Herndon, D.C. Harmon, R. Carey, J. Aisner, and J.M. Corson Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B Cancer 82 1998 1578 1584
28. N.J. Vogelzang, J.N. Herndon, C. Cirrincione, D.C. Harmon, K.H. Antman, and J.M. Corson Dihydro-5-azacytidine in malignant mesothelioma. A phase II trial demonstrating activity accompanied by cardiac toxicity. Cancer and Leukemia Group B Cancer 79 1997 2237 2242
29. L. Wong, J. Zhou, D. Anderson, and R.A. Kratzke Inactivation of p16(INK4a) expression in malignant mesothelioma by methylation Lung Cancer 38 2002 131 136
30. R. Claus, and M. Lubbert Epigenetic targets in hematopoietic malignancies Oncogene 22 2003 6489 6496
31. M. Bongiovanni, P. Cassoni, P. De Giuli, L. Viberti, S. Cappia, and C. Ivaldi p27(kip1) immunoreactivity correlates with long-term survival in pleural malignant mesothelioma Cancer 92 2001 1245 1250
32. T.W. Beer Immunohistochemical MIB-1 and p27 as prognostic factors in pleural mesothelioma Pathol Res Pract 197 2001 859
33. T.W. Beer, P. Shepherd, and N.C. Pullinger p27 immunostaining is related to prognosis in malignant mesothelioma Histopathology 38 2001 535 541
34. R. Isik, M. Metintas, A.R. Gibbs, S. Metintas, B. Jasani, and U. Oner p53, p21 and metallothionein immunoreactivities in patients with malignant pleural mesothelioma: correlations with the epidemiological features and prognosis of mesotheliomas with environmental asbestos exposure Respir Med 95 2001 588 593
35. P. Tan, B. Cady, M. Wanner, P. Worland, B. Cukor, and C. Magi-Galluzzi The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a, b) invasive breast carcinomas Cancer Res 57 1997 1259 1263
36. W.S. el-Deiry, T. Tokino, V.E. Velculescu, D.B. Levy, R. Parsons, and J.M. Trent WAF1, a potential mediator of p53 tumor suppression Cell 75 1993 817 825
37. B.C. Liu, D.C. Fu, Q. Miao, H.H. Wang, and B.R. You p53 gene mutations in asbestos associated cancers Biomed Environ Sci 11 1998 226 232
38. F.G. Mayall, G. Jacobson, and R. Wilkins Mutations of p53 gene and SV40 sequences in asbestos associated and non-asbestos-associated mesotheliomas J Clin Pathol 52 1999 291 293
39. Z. Ni, Y. Liu, N. Keshava, G. Zhou, W. Whong, and T. Ong Analysis of K-ras and p53 mutations in mesotheliomas from humans and rats exposed to asbestos Mutat Res 468 2000 87 92
40. H.I. Pass, E.J. Stevens, H. Oie, M.G. Tsokos, A.D. Abati, and P.A. Fetsch Characteristics of nine newly derived mesothelioma cell lines Ann Thorac Surg 59 1995 835 844
41. J. Creaney, B.M. McLaren, S. Stevenson, A.W. Musk, N. de Klerk, and B.W. Robinson p53 autoantibodies in patients with malignant mesothelioma: stability through disease progression Br J Cancer 84 2001 52 56
42. C.T. Yang, L. You, C.C. Yeh, J.W. Chang, F. Zhang, and F. McCormick Adenovirus-mediated p14(ARF) gene transfer in human mesothelioma cells J Natl Cancer Inst 92 2000 636 641
43. C.M. Rudin, and C.B. Thompson Apoptosis and disease: regulation and clinical relevance of programmed cell death Annu Rev Med 48 1997 267 281
44. S. Krajewski, C. Blomqvist, K. Franssila, M. Krajewska, V.M. Wasenius, and E. Niskanen Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma Cancer Res 55 1995 4471 4478
45. Y. Soini, V. Kinnula, R. Kaarteenaho-Wiik, E. Kurttila, K. Linnainmaa, and P. Paakko Apoptosis and expression of apoptosis regulating proteins bcl-2, mcl-1, bcl-X, and bax in malignant mesothelioma Clin Cancer Res 5 1999 3508 3515
46. W.R. Smythe, I. Mohuiddin, M. Ozveran, and X.X. Cao Antisense therapy for malignant mesothelioma with oligonucleotides targeting the bcl-xl gene product J Thorac Cardiovasc Surg 123 2002 1191 1198
47. I. Mohiuddin, X. Cao, B. Fang, M. Nishizaki, and W.R. Smythe Significant augmentation of pro-apoptotic gene therapy by pharmacologic bcl-xl down-regulation in mesothelioma Cancer Gene Ther 8 2001 547 554
48. A. Pataer, W.R. Smythe, R. Yu, B. Fang, T. McDonnell, and J.A. Roth Adenovirus-mediated Bak gene transfer induces apoptosis in mesothelioma cell lines J Thorac Cardiovasc Surg 121 2001 61 67
49. S. Kumar-Singh, W. Jacobs, K. Dhaene, B. Weyn, J. Bogers, and J. Weyler Syndecan-1 expression in malignant mesothelioma: correlation with cell differentiation, WT1 expression, and clinical outcome J Pathol 186 1998 300 305
50. S. Kumar-Singh, K. Segers, U. Rodeck, H. Backhovens, J. Bogers, and J. Weyler WT1 mutation in malignant mesothelioma and WT1 immunoreactivity in relation to p53 and growth factor receptor expression, cell-type transition, and prognosis J Pathol 181 1997 67 74
51. S. Kumar-Singh, P.B. Vermeulen, J. Weyler, K. Segers, B. Weyn, and A. Van Daele Evaluation of tumour angiogenesis as a prognostic marker in malignant mesothelioma J Pathol 182 1997 211 216
52. M. Mali, K. Elenius, H.M. Miettinen, and M. Jalkanen Inhibition of basic fibroblast growth factor-induced growth promotion by overexpression of syndecan-1 J Biol Chem 268 1993 24215 24222
53. G. Cox, and K.J. O'Byrne Matrix metalloproteinases and cancer Anticancer Res 21 2001 4207 4219
54. V.M. Macaulay, K.J. O'Byrne, M.P. Saunders, J.P. Braybrooke, L. Long, and F. Gleeson Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions Clin Cancer Res 5 1999 513 520
55. A. Procopio, L. Strizzi, G. Vianale, P. Betta, R. Puntoni, and V. Fontana Simian virus-40 sequences are a negative prognostic cofactor in patients with malignant pleural mesothelioma Genes Chromosomes Cancer 29 2000 173 179
56. M.J. Imperiale, H.I. Pass, and M.G. Sanda Prospects for an SV40 vaccine Semin Cancer Biol 11 2001 81 85
57. T.W. Beer, N.J. Carr, M.A. Whittaker, and N. Pullinger Mitotic and in situ end-labeling apoptotic indices as prognostic markers in malignant mesothelioma Ann Diagn Pathol 4 2000 143 148
58. K. Kahlos, P. Paakko, E. Kurttila, Y. Soini, and V.L. Kinnula Manganese superoxide dismutase as a diagnostic marker for malignant pleural mesothelioma Br J Cancer 82 2000 1022 1029
59. K. Kahlos, Y. Soini, P. Paakko, M. Saily, K. Linnainmaa, and V.L. Kinnula Apoptosis, and manganese superoxide dismutase in malignant mesothelioma Int J Cancer 88 2000 37 43
60. K. Kahlos, Y. Soini, M. Saily, P. Koistinen, S. Kakko, and P. Paakko Up-regulation of thioredoxin and thioredoxin reductase in human malignant pleural mesothelioma Int J Cancer 95 2001 198 204
61. K. Kahlos, Y. Soini, R. Sormunen, R. Kaarteenaho-Wiik, P. Paakko, and K. Linnainmaa Expression and prognostic significance of catalase in malignant mesothelioma Cancer 91 2001 1349 1357